

Dear

FREEDOM OF INFORMATION – RHEUMATOLOGY TREATMENT

I write in response to your request for information in relation to rheumatology treatment in NHS Lothian.

Question:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Abatacept [Orencia]; Adalimumab [Humira]; Adalimumab Biosimilars; Apremilast [Otezla]; Apremilast [Generic]; Baricitinib [Olumiant]; Bimekizumab [Bimzelx]; Certolizumab [Cimzia]; Etanercept [Enbrel]; Etanercept Biosimilars; Filgotinib [Jyseleca]; Golimumab [Simponi]; Golimumab Biosimilar; Guselkumab [Tremfya]; Infliximab [Remicade]; Infliximab Biosimilars; Ixekizumab [Taltz]; Risankizumab [Skyrizi]; Rituximab [MabThera]; Rituximab Biosimilars; Sarilumab [Kevzara]; Secukinumab [Cosentyx]; Tocilizumab [Ro Actemra]; Tocilizumab Biosimilars; Tofacitinib [Xeljanz]; Upadacitinib [Rinvoq]; Ustekinumab [Stelara]; Ustekinumab Biosimilar.

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Rheumatology treatment, June – August 2026, NHS Lothian	
Treatment	Number of patients
Abatacept [Orencia]	Information not available
Adalimumab [Humira]	31
Adalimumab Biosimilars	1,377
Apremilast [Otezla]	8
Apremilast [Generic]	6
Baricitinib [Olumiant]	89
Bimekizumab [Bimzelx]	55
Certolizumab [Cimzia]	197

Rheumatology treatment, June – August 2026, NHS Lothian	
Treatment	Number of patients
Etanercept [Enbrel]	19
Etanercept Biosimilars	643
Filgotinib [Jyseleca]	301
Golimumab [Simponi]	17
Golimumab Biosimilar	0
Guselkumab [Tremfya]	21
Infliximab [Remicade]	≤5
Infliximab Biosimilars	Information not available
Ixekizumab [Taltz]	≤5
Risankizumab [Skyrizi]	≤5
Rituximab [MabThera]	0
Rituximab Biosimilars	Information not available
Sarilumab [Kevzara]	44
Secukinumab [Cosentyx]	263
Tocilizumab [Ro Actemra]	≤5
Tocilizumab Biosimilars	Information not available
Tofacitinib [Xeljanz]	31
Upadacitinib [Rinvoq]	252
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	≤5

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI>

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive